AstraZeneca has followed others in saying it could suspend further investment in the United Kingdom unless the government reforms what its chairman described as an “antiquated and appalling” drug pricing system.
AstraZeneca becomes the latest to say it could halt UK investment over 'appalling' pricing regime
October 7, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Australians want better access to medical technology, and a clearer pathway to get there
October 28, 2025 - -
Pharmacy Guild backs expanded prescribing rights for optometrists
October 28, 2025 - - Latest News -
PYC reports strong clinical momentum and cash position ahead of key readouts
October 27, 2025 - - Australian Biotech -
Government backs new national push to close bone health testing gap for women
October 27, 2025 - - Latest News -
Leadership change at PolyNovo as long-time Chair steps down
October 27, 2025 - - Australian Biotech -
Cann Group announces major debt restructure and capital raise to strengthen balance sheet
October 27, 2025 - - Australian Biotech -
FDA awards the first-ever national priority vouchers to nine sponsors
October 27, 2025 - - Latest News
